Abstract
Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 is central to eosinophil maturation and release from the bone marrow, and their subsequent accumulation, activation and persistence in the tissues. Reslizumab (Cinquil, Ception Therapeutics Inc., PA, USA) is a humanized monoclonal antibody with potent IL-5 neutralizing effects that represents a potential treatment for eosinophilic diseases. This article considers the current status of the clinical development of reslizumab for pediatric eosinophilic esophagitis.
Original language | English |
---|---|
Pages (from-to) | 461-465 |
Number of pages | 5 |
Journal | Immunotherapy |
Volume | 2 |
Issue number | 4 |
DOIs | |
Publication status | Published - Jul 2010 |
Keywords
- Cinquil (TM)
- eosinophils
- IL-5
- pediatric eosinophilic esophagitis
- reslizumab
- IL-5 receptor-alpha
- human interleukin-5
- Hypereosinophilic syndrome
- decreased expression
- asthma
- hyperreactivity
- Mepolizumab
- antibody
- gastroenteritis
- aeroallergens